Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypcptide (GIP) as future antidiabetic agents

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypcptide (GIP) as future antidiabetic agents'. Together they form a unique fingerprint.

Medicine & Life Sciences